细胞色素P450抑制剂与诱导剂所致静脉药物相互作用的定量预测
本研究针对静脉给药药物,基于五大CYP酶代谢药物数据,用贝叶斯方法从口服相互作用贡献比估算静脉贡献比并验证预测模型。训练集95%的AUC比在可接受范围,验证集85%预测在范围内,抑制剂平均AUC比口服2.28、静脉1.78,诱导剂口服0.209、静脉0.62。
要点
- 静脉给药因绕过肠道降解和肝首过代谢,DDI幅度与口服不同。
- 模型验证集85%预测AUC比在观察值50-200%范围内。
- 抑制剂平均AUC比口服2.28高于静脉1.78,诱导剂口服0.209低于静脉0.62。
核心结论
- 尽管数据集有限,该模型表现稳健,85%的预测得到验证,可扩展DDI-predictor框架用于CYP介导的静脉药物DDI定量预测。
研究设计与样本
- 分析五大CYP酶代谢药物,收集静脉DDI研究的AUC比(合用/不合用 precipitant),用贝叶斯方法从已发表口服贡献比估算静脉贡献比,以预测值与观察值比值是否在50-200%范围内验证。
主要发现
- 共分析33种药物、87个AUC比,涉及26种 precipitant。
- 训练集95%的AUC比在可接受范围,平均偏倚0.09 mg·h/L,不精密度16%。
- 验证集85%的预测在范围内,偏倚-0.012 mg·h/L,不精密度27.3%。
- 抑制剂平均AUC比口服2.28、静脉1.78;诱导剂平均AUC比口服0.209、静脉0.62。
临床怎么用
- 可用于预测和理解为静脉给药 object drug 的CYP介导DDI,辅助临床评估静脉药物相互作用风险。
局限性
- 数据集有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Pharmacokinetic interaction studies typically focus on oral administration, but intravenous (IV) administration bypasses intestinal degradation and hepatic first-pass metabolism, leading to distinct drug-drug interaction (DDI) magnitude. This study aimed to develop a predictive model for DDIs involving IV-administered drugs. METHODS: Drugs metabolized by the five major cytochrome P450 enzymes were analysed. Data from IV DDI studies, including area under the concentration-time curve (AUC) ratios of object drugs with and without precipitants, were collected. A Bayesian approach estimated IV contribution ratios (CR) from published oral CR values. Predictions were validated by assessing whether predicted-to-observed ratios fell within 50-200% of observed values. RESULTS: Data for 33 drugs and 87 AUC ratios involving 26 precipitants were analysed. In the training set, 95% of AUC ratios were within the acceptability range, with a mean bias of 0.09 mg·h/L and 16% imprecision. In the validation set, 85% of predictions were within range, with a bias of -0.012 mg·h/L and 27.3% imprecision. Mean AUC ratios for inhibitors were 2.28 (oral) and 1.78 (IV). For inducers, mean AUC ratios were 0.209 (oral) and 0.62 (IV). CONCLUSIONS: Despite the limited dataset, the model demonstrated robust performance with 85% of predictions validated. It expands the DDI-predictor framework for quantitative prediction of cytochrome-mediated drug-drug interactions affecting drug exposure to intravenously administered object drugs, thereby providing a tool to predict and understand IV-specific DDIs effectively.
引用
- Tuloup V, Tod M, Bourguignon L, et al. Quantitative prediction of intravenous drug interactions caused by cytochromes P450 inhibitors and inducers. Br J Clin Pharmacol. 2026. PMID: 41934177. doi:10.1002/bcp.70548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。